Furthermore, RORC has been linked to TGF-β-induced EMT in hepatocytes during liver fibrosis, and in estrogen-receptor-negative breast cancer, and has been proposed as therapeutic target to treat these diseases [39,48,49]. Here, RORC is linked to estrogen-receptor negative breast cancer.